These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 26077415)

  • 21. Pediatric rheumatology infusion center: report on therapeutic protocols and infusions given over 4 Years with focus on adverse events over 1 Year.
    Vinod SS; Reed AB; Maxwell J; Cron RQ; Stoll ML
    Pediatr Rheumatol Online J; 2018 Mar; 16(1):16. PubMed ID: 29523211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
    García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
    Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease-A Single Center Case-Control Study.
    Szymanska E; Dadalski M; Sieczkowska-Golub J; Jarzebicka D; Meglicka M; Osiecki M; Wiernicka A; Lebensztejn DM; Korczowski B; Kierkus J
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
    Checkley LA; Kristofek L; Kile S; Bolgar W
    Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD.
    Espinoza F; Le Blay P; Combe B
    J Rheumatol; 2017 Jun; 44(6):844-849. PubMed ID: 28412711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and/or Uveitis: A Retrospective Longitudinal Cohort Study.
    Aeschlimann FA; Angst F; Hofer KD; Cannizzaro Schneider E; Schroeder-Kohler S; Lauener R; van der Kleij D; Rispens T; Saurenmann RK
    J Rheumatol; 2017 Mar; 44(3):334-341. PubMed ID: 28089968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.
    Rahman P; Choquette D; Bensen WG; Khraishi M; Chow A; Zummer M; Shaikh S; Sheriff M; Dixit S; Sholter D; Psaradellis E; Sampalis JS; Letourneau V; Lehman AJ; Nantel F; Rampakakis E; Otawa S; Shawi M
    BMJ Open; 2016 Apr; 6(4):e009661. PubMed ID: 27048632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk Factors Associated with Infusion Reactions to Infliximab in Chinese Patients with Inflammatory Bowel Disease: A Large Single-Center Study.
    Wang X; Cao J; Wang H; Ye C
    Med Sci Monit; 2019 Mar; 25():2257-2264. PubMed ID: 30917108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis.
    Lazzerini PE; Acampa M; Hammoud M; Maffei S; Capecchi PL; Selvi E; Bisogno S; Guideri F; Galeazzi M; Pasini FL
    J Rheumatol; 2008 Oct; 35(10):1958-65. PubMed ID: 18709695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of Severe Infusion Reactions Associated With Outpatient Infusion of Infliximab Without Premedications.
    Hutsell SQ; Wu M; Park KT
    J Pediatr Gastroenterol Nutr; 2017 Oct; 65(4):430-431. PubMed ID: 28937551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy.
    Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study.
    Lee TW; Singh R; Fedorak RN
    Aliment Pharmacol Ther; 2011 Jul; 34(2):181-7. PubMed ID: 21615434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis].
    Wiland P; Głowska A; Chlebicki A; Szechiński J
    Pol Arch Med Wewn; 2002 Nov; 108(5):1055-63. PubMed ID: 12685246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
    Crandall WV; Mackner LM
    Aliment Pharmacol Ther; 2003 Jan; 17(1):75-84. PubMed ID: 12492735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
    Kapetanovic MC; Larsson L; Truedsson L; Sturfelt G; Saxne T; Geborek P
    Arthritis Res Ther; 2006; 8(4):R131. PubMed ID: 16869978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
    Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ;
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience.
    El-Matary W; Dykes DMH; Bauman L; Elkadri A; Carroll MW; Izaguirre MR; deBruyn J; Samson CM; Crim AM; Ali S; Grossman A
    Inflamm Bowel Dis; 2017 Dec; 23(12):2104-2108. PubMed ID: 29140940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology.
    Lequerré T; Vittecoq O; Klemmer N; Goëb V; Pouplin S; Menard JF; Daragon A; Mejjad O; Le Loët X
    J Rheumatol; 2006 Jul; 33(7):1307-14. PubMed ID: 16758513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.